Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Site
3.2. Market Snippet by Species Type
3.3. Market Snippet by Drug Type
3.4. Market Snippet by Distribution Channel
3.5. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.2. Drivers
4.2.1. Rising incidence of Schistosomiasis
4.2.2. XX
4.3. Restraints
4.3.1. Stringent regulatory approvals
4.3.2. XX
4.4. Opportunity
4.5. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Pipeline Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Reimbursement Analysis
5.7. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Site
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site Segment
7.1.2. Market Attractiveness Index, By Site Segment
7.2. Intestinal Schistosomiasis*
7.2.1. Introduction
7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3. Urogenital schistosomiasis
8. By Species Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type Segment
8.1.2. Market Attractiveness Index, By Species Type Segment
8.2. Schistosoma mansoni*
8.2.1. Introduction
8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3. Schistosoma japonicum
8.4. Schistosoma mekongi
8.5. Schistosoma guineensis
8.6. Schistosoma haematobium
9. By Drug Type
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
9.1.2. Market Attractiveness Index, By Drug Type Segment
9.2. Praziquantel (Biltricide)*
9.2.1. Introduction
9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3. Oxamniquine (Vansil)
9.4. Metrifonate
9.5. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel Segment
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Others
11. By Region
11.1. Introduction
11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
11.3. Market Attractiveness Index, By Region
11.4. North America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. U.S.
11.4.7.2. Canada
11.4.7.3. Mexico
11.5. Europe
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. Germany
11.5.7.2. U.K.
11.5.7.3. France
11.5.7.4. Italy
11.5.7.5. Spain
11.5.7.6. Rest of Europe
11.6. South America
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.6.7.1. Brazil
11.6.7.2. Argentina
11.6.7.3. Rest of South America
11.7. Asia Pacific
11.7.1. Introduction
11.7.2. Key Region-Specific Dynamics
11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.7.7.1. China
11.7.7.2. India
11.7.7.3. Japan
11.7.7.4. Australia
11.7.7.5. Rest of Asia Pacific
11.8. Middle East and Africa
11.8.1. Introduction
11.8.2. Key Region-Specific Dynamics
11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Bayer AG*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Merck & Co., Inc.
13.3. Avanscure Lifesciences Pvt. Ltd.
13.4. Shin Poong Pharma.Co., Ltd.
13.5. Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)
13.6. CBC Pharma.
13.7. Chemos GmbH & Co. KG.
13.8. VHB Life Science Inc.
13.9. 3S Corporation Kancera AB
13.10. Taj Pharmaceuticals Ltd. (List Not Exhaustive)
14. DataM Intelligence
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us